A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).

Nobuyuki Yamamoto, Maryam Shahidi, Shinji Atagi et al.|Journal of Clinical Oncology|2011

Cited by 25